Page last updated: 2024-08-21

azomycin and Cardiomyopathies

azomycin has been researched along with Cardiomyopathies in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Bardach, A; Barreira, F; Ciapponi, A; Gascón, J; Molina, I; Morillo, C; Perelli, L; Prado, N; Riarte, A; Ribeiro, I; Sosa-Estani, S; Torrico, F; Villar, JC1
Borchardt, RA; Tzizik, DM1
Asti, L; Bartsch, SM; Bottazzi, ME; Falcón-Lezama, JA; Hotez, PJ; Lee, BY; Meymandi, S; Randall, S; Strych, U1
Arias, E; Bizai, ML; Bottasso, O; del Barco, M; Denner, S; Diez, C; Fabbro, DL; Mancipar, I; Marcipar, I; Mendicino, D; Olivera, V; Streiger, M1
Cruz-Zetina, G; del Rio-Rodriguez, R; López, R; Monteon, V; Ramos-Ligonio, A1
Kuczynski, B; Patel, B; Rumsey, WL1

Reviews

1 review(s) available for azomycin and Cardiomyopathies

ArticleYear
Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
    PLoS neglected tropical diseases, 2020, Volume: 14, Issue:8

    Topics: Adult; Cardiomyopathies; Chagas Disease; Databases, Factual; Humans; Nifurtimox; Nitroimidazoles; Patient Safety; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; Trypanosoma cruzi

2020

Other Studies

5 other study(ies) available for azomycin and Cardiomyopathies

ArticleYear
Chagas disease: An underrecognized diagnosis.
    JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:12

    Topics: Acute-Phase Reaction; Cardiomyopathies; Chagas Disease; Chronic Disease; Diagnosis, Differential; Female; Humans; Male; Megacolon; Nifurtimox; Nitroimidazoles; Trypanocidal Agents; Trypanosoma cruzi; United States

2018
Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients.
    Vaccine, 2019, 06-19, Volume: 37, Issue:28

    Topics: Cardiomyopathies; Chagas Disease; Chronic Disease; Cost-Benefit Analysis; Disease Progression; Humans; Nitroimidazoles; Trypanosoma cruzi; Vaccination; Vaccines

2019
Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage.
    The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:4

    Topics: Animals; Antibodies, Protozoan; Cardiomyopathies; Chagas Disease; Chronic Disease; Female; Humans; Immunity, Humoral; Male; Nifurtimox; Nitroimidazoles; Protozoan Proteins; Ribosomal Proteins; Trypanocidal Agents; Trypanosoma cruzi

2011
Decreased intensity of inflammation in benznidazole-treated mice inoculated with Trypanosoma cruzi I stocks from Mexico and persistence of circulating parasites.
    The American journal of tropical medicine and hygiene, 2012, Volume: 87, Issue:4

    Topics: Animals; Cardiomyopathies; Chagas Disease; Genotype; Heart; Inflammation; Mexico; Mice; Mice, Inbred BALB C; Muscle, Skeletal; Nitroimidazoles; Parasitemia; Polymerase Chain Reaction; Trypanocidal Agents; Trypanosoma cruzi

2012
Detecting hypoxia in heart using phosphorescence quenching and 99mtechnetium-nitroimidazoles.
    Advances in experimental medicine and biology, 1994, Volume: 361

    Topics: Animals; Cardiomyopathies; Disease Models, Animal; Dogs; Hypoxia; Luminescent Measurements; Myocardial Ischemia; Myocardium; Nitroimidazoles; Organotechnetium Compounds; Oxygen; Radionuclide Imaging

1994